Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
Joel Worley Beatty, San Mateo, CA (US); Samuel Lawrie Drew, Millbrae, CA (US); Matthew Epplin, South San Francisco, CA (US); Jeremy Thomas Andre Fournier, Fremont, CA (US); Balint Gal, Hayward, CA (US); Tezcan Guney, Hayward, CA (US); Karl T. Haelsig, Berkeley, CA (US); Clayton Hardman, San Francisco, CA (US); Steven Donald Jacob, Oakland, CA (US); Jenna Leigh Jeffrey, Oakland, CA (US); Jaroslaw Kalisiak, Mountain View, CA (US); Kenneth Victor Lawson, San Francisco, CA (US); Manmohan Reddy Leleti, Dublin, CA (US); Erick Allen Lindsey, San Diego, CA (US); Artur Karenovich Mailyan, Hayward, CA (US); Debashis Mandal, Fremont, CA (US); Guillaume Mata, Berkeley, CA (US); Hyunyoung Moon, Foster City, CA (US); Jay Patrick Powers, Sisters, OR (US); Brandon Reid Rosen, San Mateo, CA (US); Yongli Su, Foster City, CA (US); Anh Thu Tran, Union City, CA (US); Zhang Wang, Petaluma, CA (US); Xuelei Yan, Foster City, CA (US); and Kai Yu, Hayward, CA (US)
Assigned to Arcus Biosciences, Inc., Hayward, CA (US)
Filed by ARCUS BIOSCIENCES, INC., Hayward, CA (US)
Filed on Aug. 30, 2023, as Appl. No. 18/239,892.
Application 17/835,559 is a division of application No. 17/205,273, filed on Mar. 18, 2021, granted, now 11,407,712, issued on Aug. 9, 2022.
Application 18/239,892 is a continuation of application No. 17/835,559, filed on Jun. 8, 2022, granted, now 11,787,762.
Claims priority of provisional application 63/120,875, filed on Dec. 3, 2020.
Claims priority of provisional application 62/991,952, filed on Mar. 19, 2020.
Prior Publication US 2024/0254079 A1, Aug. 1, 2024